Drug Profile
PRX 08066
Alternative Names: PRX-08066; PRX-8066Latest Information Update: 30 Apr 2012
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Developer Clinical Data
- Class Antihypertensives; Pyrimidines; Small molecules; Thiophenes
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 30 Apr 2012 No development reported - Phase-II for Pulmonary hypertension in USA (PO)
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 02 Nov 2010 PRX 08066 receives Orphan Drug status for Pulmonary arterial hypertension in USA